Archive — US — techcrunch
From OpenAI’s offices to a deal with Eli Lilly — how Chai Discovery became oneof the flashiest names in AI drug development
Chai Discovery, an AI drug development startup founded in 2024, has rapidly gained prominence by raising hundreds of millions and partnering with Eli Lilly. Their AI algorithm, Chai-2, accelerates drug discovery by developing antibodies. With a Series B funding round raising $130 million and a valuation of $1.3 billion, Chai aims to revolutionize biopharma despite skepticism about AI's efficacy in the field.
Key points
- Chai Discovery was founded in 2024 and has quickly raised significant capital, including a Series B round of $130 million.
- The company has formed a partnership with Eli Lilly to utilize its AI algorithm, Chai-2, for drug development.
- Chai Discovery aims to streamline drug discovery, traditionally a lengthy process, leveraging AI to improve efficiency.
- Despite skepticism from some industry veterans regarding the impact of AI in drug development, investors believe in the technology's potential.
- Chai’s founders previously had connections with OpenAI, which also invested in the startup.
Why it matters
- The rise of AI in drug discovery aligns with 2025 IT trends emphasizing AI integration in healthcare and biotechnology.
- This trend echoes past advancements in biotechnology, illustrating ongoing attempts to merge technology with traditional pharmaceutical processes.
- Eli Lilly's collaboration with Chai mirrors similar corporate strategies seen in the tech sector prioritizing partnerships for innovation, such as Nvidia's $1 billion AI drug discovery lab.
Chai Discovery's swift ascent in AI-driven drug development showcases the growing intersection of biotechnology and artificial intelligence, positioning it as a key player in an evolving industry despite skepticism about its efficacy.